 Smoking cessation: How compelling is the evidence? A reviewPhilip Tønnesen Health Policy, 2009, vol. 91, issue Supplement 1, S15-S25 Abstract: Objectives To provide a short review of the evidence base supporting smoking cessation interventions, including behavioral therapy and pharmacological treatment options.Methods Published meta-analysis was mainly used supplemented with a limited literature search.Results Effective smoking cessation consists of pharmacotherapy and behavioral support. Counseling increases abstinence rates parallel to the intensity of support. First-line pharmacological drugs for smoking cessation are nicotine replacement products (patch, gum, inhaler, nasal spray, lozenge/tablets), varenicline and bupropion SR with scientific well-documented efficacy when used for 2-3 months and mostly mild side effects. Alternative therapies such as hypnosis and acupuncture have no scientifically proven effects.Conclusions With the most optimal drugs and counseling today a 1-year abstinence rate of approximately 25% can be expected in smoking cessation. On-going research is examining the potential effects of nicotine vaccination as relapse prevention. Keywords: Bupropion; Cost-effective; Counseling; Nicotine; replacement; products; Smoking; cessation; Varenicline (search for similar items in EconPapers) Downloads: (external link) Related works: Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text Persistent link: https://EconPapers.repec.org/RePEc:eee:hepoli:v:91:y:2009:i:supplement1:p:s15-s25 Access Statistics for this article Health Policy is currently edited by Katrien Kesteloot, Mia Defever and Irina Cleemput More articles in Health Policy from Elsevier |
Is your work missing from RePEc? Here is how to contribute.
Questions or problems? Check the EconPapers FAQ or send mail to .
EconPapers is hosted by the
School of Business at Örebro University.